TORCH-R trial protocol: hypofractionated radiotherapy combined with chemotherapy and toripalimab for locally recurrent rectal cancer: a prospective, single-arm, two-cohort, phase II trial

TORCH-R trial protocol: hypofractionated radiotherapy combined with chemotherapy and toripalimab for locally recurrent rectal cancer: a prospective, single-arm, two-cohort, phase II trial

For patients with locally recurrent rectal cancer (LRRC), the response rate to chemoradiotherapy is 40%–50%. Additionally, only approximately 40%–50% of patients with recurrent rectal cancer are able to undergo R0 resection. Recent studies in locally advanced rectal cancer (LARC) have shown promisin...

Full description

Bibliographic Details
Main Authors: Juefeng Wan, Ruiyan Wu, Miaomiao Fu, Lijun Shen, Hui Zhang, Yan Wang, Yaqi Wang, Shujuan Zhou, Yajie Chen, Fan Xia, Zhen Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-11-01
Series:Frontiers in Oncology
Subjects:
locally recurrent rectal cancer
immunotherapy
hypofractionated radiotherapy
chemotherapy
SAbR
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1304767/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1304767/full

Similar Items